'Important' microbiome studies offer hope for IBD prediction

By Nikki Hancocks contact

- Last updated on GMT

Getty | ChrisChrisW
Getty | ChrisChrisW

Related tags: Gut health, microbiome, IBD

We may be able to predict disease relapse in patients with chronic inflammatory bowel diseases based on their microbiome markers, according researchers from APC Microbiome Ireland.

Inflammatory bowel disease, comprised of ulcerative colitis (UC) and Crohn’s disease (CD), affects tens of thousands of patients in Ireland alone. While the condition can be controlled with drugs, the unpredictability of relapses is a major challenge for patients and is one of the reasons why the microbiome is so important in providing markers to predict relapse. Yet few large-scale longitudinal studies across stages of disease activity have been conducted, particularly with intercontinental comparisons. 

Therefore researchers from APC Microbiome Ireland, at University College Cork, led collaborative studies which they describe as "two of the most important and largest microbiome studies ever undertaken in patients with chronic inflammatory bowel disease"​. 

The most recent study, published in the journal Gut ​yesterday (June 14th), followed 700 Irish and Canadian patients with CD and UC and ranked the effect of disease activity, medications, diet and geographic location on their faecal microbiota composition at three time points with 16 weeks intervals and revealed disturbances in the microbiome associated with relapses of disease.

They collected 1815 stool samples from 303 patients with CD, 228 patients with UC and 161 healthy controls from the regions of Manitoba, Canada (59% of subjects) and Cork, Ireland. Machine learning separated disease from controls, and active from inactive disease, when consecutive time points were modelled. 

Researchers concluded that that inter-individual variance was greater than intra-individual, and that the microbiota was more unstable in CD and UC compared with controls. They conclude that geographic location contributes more to microbiota variance than common variables such as prior surgical resection, age, gender and diet. 

This backs up the findings of the center's previous study, published in Nature Communications ​in March, which showed changes in the microbes sampled at colonoscopy were directly associated with inflammation in the colon.

Dr Marcus Claesson, leader of this research at APC Microbiome Ireland, said the studies will open the way for doctors to be able to predict relapses of disease before patients develop symptoms.

“We are delighted that both of our research approaches showed complementary, albeit important, results which will be of benefit to patients in the future.

“While ethnicity, diet and geographical location were found to contribute to microbiota variation globally, it is the variation in microbiota composition within individuals followed over time which increases the power of microbiome markers to predict relapse.  This has implications for future microbiota studies and for the development of precision medicine.”

Enhanced molecular resolution

The work published in March studied paired biopsies from inflamed and non-inflamed mucosa of 80 adult patients with ulcerative colitis and 50 with Crohn’s disease, along with paired biopsies of 31 non-IBD controls, all recruited in Ireland. 

The study extended the observations thanks to its large number of paired biopsies and its inclusion of a wider array of molecular data including microbiota, host transcriptome, epigenome and genotype. It also provided enhanced molecular resolution with bacterial species classification and the usage of error-corrected reads, as opposed to representative sequences of operational taxonomic units.

They found that habitual diet appeared to have minimal relationship with observed differences in microbiota composition across the study groups, possibly due to its lesser effect on mucosa-adherent bacteria compared with fecal microbiota

The researchers concluded: "Epithelial DNA methylation improves disease classification and is associated with both inflammation and microbiota composition. Microbiota sub-groups are driven by dominant Enterbacteriaceae and Bacteroides species, representative strains of which are pro-inflammatory in vitro, are also associated with immune-related epigenetic markers. In conclusion, inflamed and non-inflamed colonic segments in both CD and UC differ in microbiota composition and epigenetic profiles."


Source 1: Nature Communications

Fergal Ryan et al 

"Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease"  



Source 2: Gut

Adam G Clooney, Julia Eckenberger et al

"Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study"​ 


Related news

Show more

Related products

show more



BIONAP Srl | 28-Oct-2021 | Data Sheet

OPUNXIA™ has a high concentrated and standardized polysaccharides profile. It is produced in powder form through specialized technologies to ensure the...

Turmacin®: Clean Label & Clinically Tested Turmeric

Turmacin®: Clean Label & Clinically Tested Turmeric

Natural Remedies Private Limited | 01-Sep-2021 | Product Presentation

Turmacin® is a clean label project-certified, clinically tested, and clinically safe turmeric extract. Turmacin® is rich in Turmerosaccharides® and doesn't...

How to Enter UK’s £690M CBD Market

How to Enter UK’s £690M CBD Market

The Association for the Cannabinoid Industry | 18-Jun-2021 | Technical / White Paper

The UK has the world’s most developed regulatory framework for legal cannabinoids, such as CBD and CBG. With a 2021 market estimated to be worth £690 million...

Related suppliers

Follow us


View more